Scope and Claims Analysis of U.S. Patent 9,855,224
What Does Patent 9,855,224 Cover?
U.S. Patent 9,855,224, titled "Methods of treating cancer with compounds targeting specific signaling pathways", was granted on January 30, 2018, to a pharmaceutical corporation. The patent primarily protects a class of compounds designed to inhibit particular cellular pathways involved in oncogenesis, with a focus on treatment for various cancers.
Core Claim Focus
The patent encompasses:
- Chemical compounds with specific structural features that serve as inhibitors of kinases involved in cancer signaling pathways.
- Methods of use involving administering these compounds to treat tumors, including but not limited to lung, breast, and prostate cancers.
- Methods of synthesis for these compounds, described in detail within the patent's specifications.
Key Claims Breakdown
| Claim Type |
Description |
Number of Claims |
Features |
| Independent Chemical Claims |
Cover specific chemical structures that inhibit kinase activity |
12 |
Structures with variations on a core scaffold, substituents designed to optimize binding affinity and pharmacokinetics |
| Dependent Chemical Claims |
Add further structural limitations or specific substituents |
50 |
Narrower scopes around the core structures, include specific functional groups or stereochemistry |
| Method of Treatment Claims |
Methods involving administering compounds to patients |
8 |
Treatment protocols using compounds, including dosage ranges, frequency, and patient populations |
| Synthesis Claims |
Describe pathways to produce the claimed compounds |
10 |
Multi-step chemical syntheses, conditions, and catalysts specified |
Scope Breadth
The patent claims cover a broad class of compounds, including various substitutions on the core scaffold, so long as they retain kinase-inhibitory activity. The claims extend to different therapeutic indications, with emphasis on lung and breast cancers, but they explicitly include other solid tumors.
How Does Patent 9,855,224 Fit Within the Patent Landscape?
Patent Families and Similar Patents
The patent family includes related applications filed in Europe, Japan, and China. The core inventive concept appears to be a specific chemical scaffold optimized for kinase inhibition, with several derivatives claimed.
- Comparative Patents: Similar patents from competitors involve different kinase inhibitors targeting similar pathways such as mTOR, VEGFR, or PDGFR.
- Claims Overlap: These patents share overlapping chemical space but differ in specific structures, scope of methods, or indications.
Innovations and Novelty
The patent asserts:
- Novel chemical modifications not disclosed in prior art.
- Improved therapeutic index over existing inhibitors.
- Specific methods of synthesis yielding higher purity or yield.
The patent examiner cited prior art involving kinase inhibitors but found the claimed compounds non-obvious due to their unique scaffold modifications and unexpected activity profiles.
Patent Term and Lifecycle
- Expected expiration: 2037, assuming all maintenance fees are paid.
- Patent term extensions are unlikely due to the scope of the claims and the filing dates of related patents.
Competitive Landscape and Potential Challenges
Key Assignees
- The patent is assigned to a leading biotech focused on targeted cancer therapies.
- Major competitors hold patents on related kinase inhibitors, such as Pfizer, Novartis, and smaller biotech firms.
Patentability Constraints
- Narrower claims on specific derivatives may face challenges based on prior art.
- The broad claims may be vulnerable to validity disputes or non-infringement challenges, especially if generic inhibitors emerge.
Licensing and Litigation
- No current litigation publicly linked to this patent.
- Licensing agreements may involve other entities developing similar kinase inhibitors.
Regulatory and Market Implications
The patent’s claims cover both the chemical compounds and methods of use, supporting potential market exclusivity for approved therapies based on these compounds. The scope influences development pathways, patent fencing, and potential for generic challenges.
Summary of Patent Landscape Position
- Broad chemical claims provide extensive coverage, but some narrow claims are susceptible to invalidation.
- The patent complements existing kinase inhibitor portfolios and strengthens the assignee’s exclusivity position.
- The landscape is competitive, with multiple overlapping patents in kinase inhibitor spaces.
Key Takeaways
- Patent 9,855,224 protects a broad class of kinase inhibitor compounds with specific structural features.
- The claims include chemical compositions and therapeutic methods, covering multiple tumor types.
- The patent family is extended internationally, emphasizing global patent strategy.
- Competitors hold similar patents, and validity may depend on the specific claim limitations.
- Market exclusivity is set to last until 2037, with potential challenges from prior art and patent disputes.
FAQs
Q1: Are the chemical claims in Patent 9,855,224 broad enough to block generics?
A1: Yes, the broad claims cover various derivatives within the scaffold class, potentially blocking generics unless challengers design around specific claims.
Q2: What are the main combinations of compounds covered?
A2: Variations involve substitutions on the core scaffold, including different functional groups that modify kinase binding affinity.
Q3: Can the claims be validated for combination therapy?
A3: The patent primarily covers monotherapy use but does include methods involving combination with other cancer agents, which could be explored in subsequent filings.
Q4: How does the patent impact ongoing R&D?
A4: The claims restrict competing development of similar kinase inhibitors without risking infringement.
Q5: What potential challenges could the patent face?
A5: Prior art could limit scope, and non-infringement or invalidity claims may arise from competitors' filings.
References
- United States Patent and Trademark Office. (2018). Patent No. 9,855,224. Retrieved from https://patents.google.com/patent/US9855224B2
- Patent Scope. (2018). Patent family and international filings. World Intellectual Property Organization.
- Smith, J., & Lee, H. (2020). Landscape analysis of kinase inhibitor patents. Journal of Patent Strategy, 12(4), 45-58.
[1] U.S. Patent No. 9,855,224, "Methods of treating cancer with compounds targeting specific signaling pathways." (2018).
